DB17666InvestigationalProtein Based Therapies
SYNB1353 is a strain of the probiotic bacteria Escherichia coli (E. coli) type Nissle and an engineered probiotic drug. Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for... It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.
- Code names
- SYNB1353
What you can answer from here — as of April 23, 2025
Which companies are running trials of SYNB1353, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account